These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29378530)

  • 41. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
    Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.
    Lyu J; Zhang Q; Jin H; Xu Y; Chen C; Ji X; Zhang X; Rao Y; Zhao P
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1469-1477. PubMed ID: 29948178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
    Mititelu M; Chaudhary KM; Lieberman RM
    J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
    Eldweik L; Mantagos IS
    Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Laser treatment or intravitreal VEGF inhibition for aggressive posterior retinopathy of prematurity?].
    Barth T; Hufendiek K; Helbig H; Oberacher-Velten I
    Ophthalmologe; 2015 Jun; 112(6):520-4. PubMed ID: 25573085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reactivation of retinopathy of prematurity after bevacizumab injection.
    Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R
    Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SAFER-ROP: Updated Protocol for Anti-VEGF Injections for Retinopathy of Prematurity.
    Beck KD; Rahman EZ; Ells A; Mireskandari K; Berrocal AM; Harper CA
    Ophthalmic Surg Lasers Imaging Retina; 2020 Jul; 51(7):402-406. PubMed ID: 32706898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-vascular endothelial growth factor (VEGF) drugs compared to laser photocoagulation for treatment of type 1 retinopathy of prematurity.
    González C R; Díaz C M; Garretón C R
    Medwave; 2022 Jan; 22(1):e8507. PubMed ID: 35100244
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity.
    Gundlach BS; Kokhanov A; Altendahl M; Suh SY; Fung S; Demer J; Pineles S; Khitri M; Chu A; Tsui I
    Am J Ophthalmol; 2022 Jun; 238():86-96. PubMed ID: 34788594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.
    Abri Aghdam K; Khadamy J; Falavarjani KG; Tsui I
    J AAPOS; 2016 Dec; 20(6):539-540.e3. PubMed ID: 27810419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial.
    Mintz-Hittner HA
    Eur J Ophthalmol; 2012; 22(5):685-6. PubMed ID: 22669847
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [VEGF antibodies as therapy for retinopathy of prematurity].
    Oberacher-Velten IM; Helbig H
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TEN-YEAR EPIDEMIOLOGY OF RETINOPATHY OF PREMATURITY TREATMENT IN TAIWAN.
    Kang EY; Hsu KH; Chu SM; Lien R; Wang NK; Lai CC; Chen KJ; Hwang YS; Lin CM; Wu WC
    Retina; 2020 Sep; 40(9):1804-1811. PubMed ID: 31764611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
    Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current and future trends in treatment of severe retinopathy of prematurity.
    Wallace DK; Wu KY
    Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravitreal anti-VEGF treatment for retinopathy of prematurity in infants with active adenoviral keratoconjunctivitis.
    Koçluk Y; Alyamaç Sukgen E
    Cutan Ocul Toxicol; 2018 Mar; 37(1):15-18. PubMed ID: 28393562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity: A Meta-analysis.
    Tsai CY; Yeh PT; Tsao PN; Chung YE; Chang YS; Lai TT
    Ophthalmology; 2021 Jun; 128(6):877-888. PubMed ID: 33212122
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-angiogenic therapy in the management of retinopathy of prematurity.
    Drenser KA
    Dev Ophthalmol; 2009; 44():89-97. PubMed ID: 19494656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.